Formulation and Evaluation of Nanosuspension of Prednisolone Acetate for Ocular Delivery
Kamlesh Patkari, Jayesh Dwivedi, Hitendra Mahajan
Abstract:
This study aimed to prepare a nanosuspension formulation as a vehicle for the improvement of the ocular delivery of Prednisolone acetate. A high-pressure homogenization technique was used to produce nanosuspensions. Five formulations were prepared using different concentrations of surfactants Pluronic and evaluated for pH, particle size, drug content, differential scanning calorimetry (DSC), X-ray diffractometry (XRD), drug release, drug permeation, and stability. Also, the HET-CAM test was used to evaluate the irritation of eyes by formulations as an alternative to the draize eye test. Optimised formulations showed a small mean size that is well suited for ocular application. Drug content is good with sustained release of the drug. Sterility testing reveals suitability for ocular administration. CAM test demonstrated non-irritancy of ophthalmic nanosuspension. There were no appreciable changes in appearance, mean particle size, PDI, and pH after three months of stability testing. It was concluded that the use of Pluronic F 68 in the formulations does not show eye irritation and could be useful to achieve a suitable nanosuspension of PA as a novel ocular delivery system.
Keywords: Nanosuspension, Pluronic F68, Prednisolone Acetate.
References:
[1] Gayton JL. A clinical comparison of two different prednisolone acetate formulations in patients undergoing cataract surgery. Curr Med Res Opin. 2005;21(8):1291–5.
[2] Kassem M, Rahman AA, Ghorab M, Ahmed M, Khalil R. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340(1–2):126–33.
[3] Sheppard J, Garg S, Lievens C, Brandano L, Wirostko B, Korenfeld M, et al. Iontophoretic dexamethasone phosphate compared to topical prednisolone acetate 1% for non-infectious anterior segment uveitis. Am J Ophthalmol. 2020; 211:76–86.
[4] Jumelle C, Gholizadeh S, AnnabiN. DanaR. Journal of Controlled Release: Advances and limitations of drug delivery systems formulated as eye drops; 2020.
[5] Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol. 2013; 2(2): 47-64.
[6] Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004; 3(9): 785-796.
[7] M. Bisrat and C. Nyström, “Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions,” Int. J. Pharm., 1988,47, 1–3,223–231.
[8] Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchêne D. Mucoadhesion of colloidal particulate systems in the gastrointestinal tract”, Eur J Pharm Biopharm. 1997; 44(1): 25 31.
[9] Kassem M, Abdel Rahman A, Ghorab M, Ahmed M, Khalil R. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007; 340(1): 126-133.
[10] Das S, Suresh PK, Deshmukh R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine.2010, 6:318–323.
[11] Hitendra S. Mahajan, Sachin R. Deshmukh Development and evaluation of gel-forming ocular films based on xyloglucan, Carbohydrate Polymers 2015,122, 243– 247.
[12] Ritger, P.L., Peppas N. A. Simple equation for solute release Part 1. Fickian and nonfickian release from non swellable devices in the form of slabs, spheres, cylinders, or disks. Journal of Control Release, 1987, 5, 37-42.
[13] Gupta H, Aquil M, Khar RK, Ali A, Bhatnagar A, Mittal G.. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine. 2010,6:324–333.
[14] Kurniawansyah, I.S., Rusdiana, T., Abnaz, Z.D., Sopyan, I. and Subarnas, A. Study of isotonicity and ocular irritation of chloramphenicol in situ gel. International Journal of applied Pharmaceutics, 2021.13(1), 103–107.
[15] Saisivam, S., Manikanndan, R, V,M., Nagarajan, M. Design and evaluation of ciprofloxacin hydrochloride ocusert. Indian Journal Pharmaceutics Sciences.1990, 61, 34-38.
[16] Budai P, Lehel J, Tavaszi J, Kormos E. HETCAM test for determining the possible eye irritancy of pesticides. Acta Vet Hung. 2010,58(3): 369–377.
[17] Goh J-Y, Weaver RJ, Dixon L, Platt NJ, Roberts RA. Development and use of in vitro alternatives to animal testing by the pharmaceutical industry. Toxicol Res.2015, 4(5):1297–1307.
[18] Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 2002;23(15):3247-3255.
[19] Bodmeier R., Chen H. Indomethacin polymeric nanosuspensions prepared by microfluidization. Journal of Controlled Release,1990, 12,3, 223- 233.
[20] Klug H. P., Alexander L. E. “X-ray diffraction procedures for polycrystalline and amorphous materials”, 1974, Wiley Interscience, NY.
[21] Peppas, N.A. Analysis of fickian and nonfickian drug release from polymers. Pharmaceutica Acta Helvetica.1985, 60, 110–111.